Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.31 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13328197 | 0.89 | L3MBTL3 (0.39) | L3MBTL3L3MBTL1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL13328201 | 0.79 | — | — | |
| SCHEMBL24630115 | 0.78 | PIM1 (0.31) | L3MBTL3 | |
| SCHEMBL26167930 | 0.78 | TSHR (0.42) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL16849112 | 0.77 | ALDH1A1 (0.48) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL16849117 | 0.77 | DPP4 (0.35) | MEN1KMT2A | |
| SCHEMBL22699009 | 0.77 | L3MBTL3 (0.48) | L3MBTL3L3MBTL1CDYLCDY1; CDY1B | |
| SCHEMBL4546641 | 0.76 | L3MBTL3 (0.53) | L3MBTL3L3MBTL1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL21573595 | 0.75 | MEN1 (0.31) | MEN1KMT2A | |
| SCHEMBL13328190 | 0.75 | GNAI3 (0.36) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180134716-A1 | COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION | MILLENNIUM PHARMACEUTICALS, INC. | 2018-05-17 | — | — | US | disclosed |
| US-9765078-B2 | Compounds and methods for inhibiting mitotic progression | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20160185782-A1 | COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION | MILLENNIUM PHARMACEUTICALS, INC. | 2016-06-30 | — | — | US | disclosed |
| US-9102678-B2 | Compounds and methods for inhibiting mitotic progression | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-08-11 | — | — | US | disclosed |
| US-20140046055-A1 | COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-8399659-B2 | Compounds and methods for inhibiting mitotic progression | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-7718648-B2 | Pyridobenzazepine compounds and methods for inhibiting mitotic progression | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-20090299060-A1 | COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| US-7572784-B2 | Compounds and methods for inhibiting mitotic progression | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-20080045501-A1 | Pyridobenzazepine compounds and methods for inhibiting mitotic progression | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-02-21 | — | — | US | disclosed |
| US-20070185087-A1 | Compounds and methods for inhibiting mitotic progression | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185087-A1 | Compounds and methods for inhibiting mitotic progression | AURKC, AURKA, AURKB | L3MBTL3 2518/4885L3MBTL1 2658/4885MEN1 717/4885 |
| US-20140046055-A1 | COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION | AURKC, AURKA, AURKB | L3MBTL3 2518/4885L3MBTL1 2658/4885MEN1 717/4885 |
| US-20080045501-A1 | Pyridobenzazepine compounds and methods for inhibiting mitotic progression | AURKB, AURKC, AURKA | L3MBTL3 2100/4885L3MBTL1 2286/4885MEN1 1012/4885 |
| US-20180134716-A1 | COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION | AURKC, AURKA, AURKB | L3MBTL3 2518/4885L3MBTL1 2658/4885MEN1 717/4885 |
| US-20090299060-A1 | COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION | AURKC, AURKA, AURKB | L3MBTL3 2518/4885L3MBTL1 2658/4885MEN1 717/4885 |
| US-20160185782-A1 | COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION | AURKC, AURKA, AURKB | L3MBTL3 2518/4885L3MBTL1 2658/4885MEN1 717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.